205 related articles for article (PubMed ID: 35183243)
1. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.
Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF
J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062
[TBL] [Abstract][Full Text] [Related]
3. Low serum exosomal miR-484 expression predicts unfavorable prognosis in ovarian cancer.
Zhang W; Su X; Li S; Liu Z; Wang Q; Zeng H
Cancer Biomark; 2020; 27(4):485-491. PubMed ID: 32065786
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
5. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
6. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
7. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
[TBL] [Abstract][Full Text] [Related]
8. Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer.
Maeda K; Sasaki H; Ueda S; Miyamoto S; Terada S; Konishi H; Kogata Y; Ashihara K; Fujiwara S; Tanaka Y; Tanaka T; Hayashi M; Ito Y; Kondo Y; Ochiya T; Ohmichi M
J Ovarian Res; 2020 Apr; 13(1):47. PubMed ID: 32336272
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
10. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
11. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
12. Approaches to the detection of ovarian cancer.
Høgdall E
Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
[TBL] [Abstract][Full Text] [Related]
13. The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer.
Wang W; Yin Y; Shan X; Zhou X; Liu P; Cao Q; Zhu D; Zhang J; Zhu W
Am J Med Sci; 2019 Oct; 358(4):256-267. PubMed ID: 31353030
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
15. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
17. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
18. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
20. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]